ACGN
Price:
$0.3849
Market Cap:
$3.24M
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. a...[Read more]
Industry
Biotechnology
IPO Date
1996-01-25
Stock Exchange
NASDAQ
Ticker
ACGN
According to Aceragen, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.04. This represents a change of -93.50% compared to the average of -0.69 of the last 4 quarters.
The mean historical PE Ratio of Aceragen, Inc. over the last ten years is -4.20. The current -0.04 PE Ratio has changed 6.62% with respect to the historical average. Over the past ten years (40 quarters), ACGN's PE Ratio was at its highest in in the March 2020 quarter at 1.13. The PE Ratio was at its lowest in in the September 2015 quarter at -8.71.
Average
-4.20
Median
-3.11
Minimum
-11.15
Maximum
0.29
Discovering the peaks and valleys of Aceragen, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 772.38%
Maximum Annual PE Ratio = 0.29
Minimum Annual Increase = -384.68%
Minimum Annual PE Ratio = -11.15
Year | PE Ratio | Change |
---|---|---|
2022 | -0.83 | -384.68% |
2021 | 0.29 | -126.45% |
2020 | -1.10 | 19.85% |
2019 | -0.92 | -25.30% |
2018 | -1.23 | -76.66% |
2017 | -5.27 | 5.74% |
2016 | -4.99 | -31.93% |
2015 | -7.32 | -22.51% |
2014 | -9.45 | -15.25% |
2013 | -11.15 | 772.38% |
The current PE Ratio of Aceragen, Inc. (ACGN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-0.55
5-year avg
-0.76
10-year avg
-4.20
Aceragen, Inc.’s PE Ratio is less than Addex Therapeutics Ltd (221.54), less than ERYTECH Pharma S.A. (27.87), greater than Soligenix, Inc. (-0.65), greater than Avenue Therapeutics, Inc. (-0.24), greater than Akari Therapeutics, Plc (-1.11), greater than Armata Pharmaceuticals, Inc. (-1.28), greater than Anebulo Pharmaceuticals, Inc. (-5.95), less than Scopus BioPharma Inc. (-0.00), greater than Processa Pharmaceuticals, Inc. (-0.32), greater than Neoleukin Therapeutics, Inc. (-0.98), greater than Senti Biosciences, Inc. (-0.18), less than Hillstream BioPharma, Inc. (-0.00), greater than SAB Biotherapeutics, Inc. (-0.95), greater than Quoin Pharmaceuticals, Ltd. (-0.44), greater than Cocrystal Pharma, Inc. (-1.06), greater than iBio, Inc. (-0.40), greater than Bio-Path Holdings, Inc. (-0.14), greater than Tempest Therapeutics, Inc. (-0.68), greater than RenovoRx, Inc. (-3.02), greater than Acrivon Therapeutics, Inc. Common Stock (-4.09), greater than Acurx Pharmaceuticals, Inc. (-1.72),
Company | PE Ratio | Market cap |
---|---|---|
221.54 | $18.70M | |
27.87 | $47.38M | |
-0.65 | $8.28M | |
-0.24 | $3.19M | |
-1.11 | $28.90M | |
-1.28 | $86.12M | |
-5.95 | $49.01M | |
-0.00 | $16.83K | |
-0.32 | $3.63M | |
-0.98 | $8.20M | |
-0.18 | $10.39M | |
-0.00 | $4.17M | |
-0.95 | $38.39M | |
-0.44 | $2.88M | |
-1.06 | $18.92M | |
-0.40 | $24.03M | |
-0.14 | $3.71M | |
-0.68 | $25.34M | |
-3.02 | $24.47M | |
-4.09 | $242.20M | |
-1.72 | $29.57M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aceragen, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aceragen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Aceragen, Inc.'s PE Ratio?
How is the PE Ratio calculated for Aceragen, Inc. (ACGN)?
What is the highest PE Ratio for Aceragen, Inc. (ACGN)?
What is the 3-year average PE Ratio for Aceragen, Inc. (ACGN)?
What is the 5-year average PE Ratio for Aceragen, Inc. (ACGN)?
How does the current PE Ratio for Aceragen, Inc. (ACGN) compare to its historical average?